Galmed Competitors
| GLMD Stock | USD 0.60 0.01 1.05% |
Galmed Pharmaceuticals vs NKGen Biotech, Correlation
Pay attention - limited upside
The correlation between Galmed Pharmaceuticals and NKGN is -0.74 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Galmed Pharmaceuticals and NKGN in the same portfolio, assuming nothing else is changed.
Moving together with Galmed Stock
Moving against Galmed Stock
| 0.63 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.59 | DSGN | Design Therapeutics | PairCorr |
| 0.53 | ENGN | enGene Holdings Common | PairCorr |
| 0.44 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.37 | KYTX | Kyverna Therapeutics | PairCorr |
Galmed Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Galmed Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Galmed and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Galmed Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Galmed Stock performing well and Galmed Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Galmed Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BIVI | 3.41 | (0.29) | 0.00 | 0.79 | 0.00 | 7.41 | 23.28 | |||
| TOVX | 5.83 | (0.64) | 0.00 | (0.11) | 0.00 | 10.53 | 37.45 | |||
| MLEC | 9.12 | 0.11 | 0.02 | 0.12 | 10.91 | 15.63 | 152.55 | |||
| CMMB | 3.51 | (0.92) | 0.00 | (0.41) | 0.00 | 7.74 | 21.53 | |||
| INM | 4.45 | (0.84) | 0.00 | (0.46) | 0.00 | 7.48 | 30.84 | |||
| BDRX | 8.78 | (1.30) | 0.00 | (0.58) | 0.00 | 11.45 | 128.35 | |||
| VRAX | 5.46 | (1.01) | 0.00 | (0.25) | 0.00 | 7.89 | 92.80 | |||
| ELAB | 6.12 | (3.89) | 0.00 | (0.93) | 0.00 | 7.40 | 53.38 | |||
| ISPC | 5.50 | (0.92) | 0.00 | (0.37) | 0.00 | 11.54 | 37.80 | |||
| NKGN | 4.98 | 2.05 | 0.00 | 11.32 | 0.00 | 20.00 | 68.90 |
Cross Equities Net Income Analysis
Compare Galmed Pharmaceuticals and related stocks such as Biovie Inc, Theriva Biologics, and Moolec Science SA Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIVI | (70 K) | (70 K) | (70 K) | (321.9 K) | (233 K) | (431.9 K) | (1.3 M) | (2.4 M) | (2.4 M) | (16.7 M) | (130.2 M) | (26.1 M) | (50.3 M) | (32.1 M) | (17.5 M) | (15.8 M) | (16.6 M) |
| TOVX | (3.9 M) | (8.1 M) | (17.1 M) | (12.3 M) | (19.8 M) | (43.7 M) | (27.3 M) | (15.2 M) | (13.4 M) | (15.3 M) | (10 M) | (14.2 M) | (19.7 M) | (18.3 M) | (25.7 M) | (23.1 M) | (21.9 M) |
| MLEC | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (4.5 M) | (51.8 M) | (7.3 M) | (111.5 M) | (100.3 M) | (95.3 M) |
| CMMB | (3 M) | (6 M) | 24.2 M | (5.8 M) | (6 M) | (7.5 M) | (4.7 M) | (9.8 M) | 13.3 M | 27.1 M | (6 M) | (12.5 M) | (27.6 M) | (24.2 M) | (13.9 M) | (12.6 M) | (11.9 M) |
| INM | (4.3 M) | (189.9 K) | (46.7 K) | (1.2 M) | (3.5 M) | (1.8 M) | (3.4 M) | (6.7 M) | (10 M) | (8.9 M) | (12.6 M) | (18.6 M) | (7.9 M) | (7.7 M) | (8.2 M) | (7.3 M) | (7 M) |
| BDRX | (4 M) | (4 M) | (4 M) | (4.1 M) | (8.8 M) | (10.1 M) | (6.2 M) | (11.7 M) | (10.4 M) | (10.1 M) | (22.2 M) | (5.5 M) | (7.7 M) | (7.1 M) | (5.7 M) | (5.2 M) | (5.4 M) |
| VRAX | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (651 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.1 M) | (5.5 M) | (5.7 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| ISPC | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (4.7 M) | (4.7 M) | (9 M) | (10.2 M) | (11.1 M) | (12.5 M) | (11.2 M) | (11.8 M) |
Galmed Pharmaceuticals and related stocks such as Biovie Inc, Theriva Biologics, and Moolec Science SA Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Galmed Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Galmed Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Galmed Pharmaceuticals Competitive Analysis
The better you understand Galmed Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Galmed Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Galmed Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Galmed Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Galmed Pharmaceuticals Competition
Galmed Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Galmed Pharmaceuticals in relation to its competition. Galmed Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Galmed Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Galmed Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Galmed Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Galmed Pharmaceuticals position
In addition to having Galmed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Galmed Pharmaceuticals Correlation with its peers. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Biotechnology sector continue expanding? Could Galmed diversify its offerings? Factors like these will boost the valuation of Galmed Pharmaceuticals. Market participants price Galmed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Galmed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Galmed Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Galmed's balance sheet. Smart investors calculate Galmed Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Galmed Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.